Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
The Daily Biotech Pulse: Protagonist’s Ulcerative Colitis Study Disappoints, Gilead’s Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida’s Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours:
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering rate hike fears.
BTIG Maintains Buy on Magenta Therapeutics, Lowers Price Target to $6
BTIG analyst Yun Zhong maintains Magenta Therapeutics (NASDAQ:MGTA) with a Buy and lowers the price target from $10 to $6.
Magenta Therapeutics Trims R&D, Cuts Workforce
Magenta Therapeutics Inc (NASDAQ:MGTA) is cutting 14% of staff and axing a planned dosing optimization trial for a stem…